Literature DB >> 7190650

Tolerance to fluphenazine and supersensitivity to apomorphine in central dopaminergic systems after chronic fluphenazine decanoate treatment.

S C Wheeler, R H Roth.   

Abstract

Fluphenazine decanoate was administered chronically to rats on a schedule for which marked tolerance developed to acute fluphenazine effects on several parameters of dopaminergic neuronal function. DOPAC and HVA levels, indicators of dopaminergic activity, were quantitated in terminal areas of the mesocortical, mesolimbic and nigrostriatal systems. With this fluphenazine regimen tolerance developed not only in the nigrostriatal and mesolimbic but also in the mesocortical dopamine system to the elevation of metabolite levels induced by acute fluphenazine administration. Evidence was obtained that tolerance was functional rather than metabolic and was characterized by a large reduction in the accumulation of metabolites which normally follows a challenge dose of fluphenazine. Other experiments suggested that the results were not due to the effects of chronic fluophenazine on the noradrenergic innervation of the cortex and were not explained by altered catabolism or clearance of the dopamine metabolites. During withdrawal from chronic fluphenazine decanoate treatment supersensitivity to apomorphine developed in the striatum. The time courses of the disappearance of apomorphine supersensitivity and of the reversal of tolerance to a fluphenazine challenge were different.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7190650     DOI: 10.1007/bf00569724

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  41 in total

1.  Long-term effects of teflutixol on the synthesis and endogenous levels of mouse brain catecholamines.

Authors:  J Hyttel
Journal:  J Neurochem       Date:  1975-11       Impact factor: 5.372

2.  On the relevance of preferential increases of mesolimbic versus striatal dopamine turnover for the prediction of antipsychotic activity of psychotropic drugs.

Authors:  P C Waldmeier; L Maître
Journal:  J Neurochem       Date:  1976-08       Impact factor: 5.372

3.  Long-term changes in the sensitivity of pre-and postsynaptic dopamine receptors in mouse striatum evidenced by behavioural and biochemical studies.

Authors:  M P Martres; J Costentin; M Baudry; H Marcais; P Protais; J C Schwartz
Journal:  Brain Res       Date:  1977-11-11       Impact factor: 3.252

Review 4.  Theoretical implications of the use of L-dopa in parkinsonism. A review.

Authors:  H Klawans; M M Ilahi; D Shenker
Journal:  Acta Neurol Scand       Date:  1970       Impact factor: 3.209

5.  Stereotaxic mapping of the monoamine pathways in the rat brain.

Authors:  U Ungerstedt
Journal:  Acta Physiol Scand Suppl       Date:  1971

6.  Presynaptic dopamine receptors. Development of supersensitivity following treatment with fluphenazine decanoate.

Authors:  M C Nowycky; R H Roth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-11       Impact factor: 3.000

7.  Central dopaminergic neurons: effects of alterations in impulse flow on the accumulation of dihydroxyphenylacetic acid.

Authors:  R H Roth; L C Murrin; J R Walters
Journal:  Eur J Pharmacol       Date:  1976-03       Impact factor: 4.432

8.  Phenothiazine antagonism of the noradrenergic inhibition of cerebellar Purkinje neurons.

Authors:  R Freedman; B J Hoffer
Journal:  J Neurobiol       Date:  1975-05

9.  Turnover of acid dopamine metabolites in striatal and mesolimbic tissue of the rat brain.

Authors:  B H Westerink; J Korf
Journal:  Eur J Pharmacol       Date:  1976-06       Impact factor: 4.432

10.  [Receptor-blockade and receptor-hypersensitivity following neuroleptic treatment (author's transl)].

Authors:  I M Nielsen; A V Christensen; J Hyttel
Journal:  Arzneimittelforschung       Date:  1976
View more
  10 in total

1.  Activation of forebrain dopamine systems by phencyclidine and footshock stress: evidence for distinct mechanisms.

Authors:  M B Bowers; M J Bannon; F J Hoffman
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  Presynaptic dopamine receptors: insensitivity to kainic acid and the development of supersensitivity following chronic haloperidol.

Authors:  M J Bannon; E B Bunney; J R Zigun; L R Skirboll; R H Roth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1980-06       Impact factor: 3.000

3.  Regional homovanillic acid levels and oral movements in rats following chronic haloperidol treatment.

Authors:  S A Kolenik; F J Hoffman; M B Bowers
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

4.  Altered spontaneous behavior and sensitivity to apomorphine in rats following pretreatment with S(+)-aporphines or fluphenazine.

Authors:  A Campbell; R J Baldessarini; J L Neumeyer
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Lithium does not interact with haloperidol in the dopaminergic pathways of the rat brain.

Authors:  A Reches; V Jackson-Lewis; S Fahn
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

6.  Homovanillic acid in caudate and pre-frontal cortex following acute and chronic neuroleptic administration.

Authors:  M B Bowers; F J Hoffman
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

7.  Progressive changes in the acute dyskinetic syndrome as a function of repeated elicitation in squirrel monkeys.

Authors:  R Neale; S Gerhardt; S Fallon; J M Liebman
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

8.  Homovanillic acid in rat caudate and prefrontal cortex following phencyclidine and amphetamine.

Authors:  M B Bowers; F J Hoffman
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

9.  Acceleration by stress of dopamine synthesis and metabolism in prefrontal cortex: antagonism by diazepam.

Authors:  J F Reinhard; M J Bannon; R H Roth
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-03       Impact factor: 3.000

10.  Nigral actions of GABA agonists are enhanced by chronic fluphenazine and differentiated by concomitant flurazepam.

Authors:  D M Coward
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.